News

The pharmaceutical company follows Johnson & Johnson's pursuit of fields outside of hepatitis C.

Researchers work showed how misalignment between a person’s lifestyle and the biological clock could affect well-being and contribute to the risks for various diseases.

The sNDA is seeking an indication for the reduction of major adverse events, including cardiovascular death, myocardial infarction, and stroke.

James Underberg, MD, President-Elect of the National Lipid Association, Clinical Assistant Professor of Medicine, NYU School of Medicine, NYU Center for the Prevention of Cardiovascular Disease, discusses statin intolerance and the future of cholesterol treatments.

The Canadian-based pharmaceutical company plans to produce a low-cost, multi-strain coverage vaccine with the grant.

The Erin Lavik-led team's proposal included screen-printing layers of adult neural progenitor-derived retinal neurons that parallel the human retina structure.

A CDC epidemiologist provides details of investigating the case of a "brain-eating" amoeba contracted in a whitewater recreation park.

The Certified Nurse Practicioner from the Henry Ford Medical Center also weighs in the best advice to avoid cardiovascular disease.

There's a growing chance that living patients can be tested for the neurodegenerative disease most linked to tackle football.

A new guideline from the Infectious Diseases Society of America addresses management of chronic pain in patients living with HIV.

Randy Lieberman, MD, the director of electrophysiology at the Detroit Medical Center, discusses the nature of treating hyperkalemia, and the future plans to improve the landscape for physicians.

Catch up on our biggest headlines you missed before the end of the month!

Price was found to have chartered more than 2 dozen flights, racking up roughly $400,000 in extraneous costs.

This is potentially the first therapy seeking FDA-approval utilizing human gut microbiome.

The Novo Nordisk product showed a greater reduction in overall blood sugar compared to the conventional insulin in clinical trials.

The treatment for Dravet syndrome showed 63.9% average reduction in monthly seizures, as well as a seizure-free period at 20.5 days.

Improvement in DAS28 scores was statistically significant in 26% of patients using adalimumab every 3 weeks compared to every 2 weeks.

Organized by the Harvard T.H. Chan School of Public Health, a panel of experts projected a foggy future for the ACA.

First-in-class antibody demonstrates significant reduction in bullous pemphigoid activity.

Data on ataluren, a first-in-class oral treatment for Duchenne muscular dystrophy, was considered inconclusive by a vote of 10-1.

The study is among the first to provide scientific evidence for medication-free approach to condition.

Amgen biosimilar Amgevita may be on US markets in about 7 years.

PURE study results showed that patients who met or exceeded recommended physical activity guidelines had a lower risk of CV events and mortality.

The investigational monotherapy has potential to be taken in multiple forms by CABP patients.

The FreeStyle Libre Flash Glucose Monitoring System reduces the requirement of “fingerstick” testing, with small sensor wire that continuously monitors and measures levels.

APTIOM provides an important new treatment option for partial-onset seizures in pediatric patients ages 4 and up for adjunctive and monotherapy use.

The HVAD System, a left ventricular assist device, assists patient’s hearts in pumping and increasing blood flow through the body.

Therapy for both relapsing and progressive forms of multiple sclerosis have progressed in recent years.

Development of surotomycin has been discontinued based on trial results.

The results of 2 studies determined that resistance training can improve lower limb function and cortical thickness in MS patients.